Literature DB >> 9657115

Human and murine antibody recognition is focused on the ATPase/helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein.

M Chen1, M Sällberg, A Sönnerborg, L Jin, A Birkett, D Peterson, O Weiland, D R Milich.   

Abstract

The hepatitis C virus (HCV) nonstructural (NS) 3 protein has been shown to possess at least two enzymatic domains. The amino terminal third contains a serine-protease domain, whereas the carboxy terminal two thirds is comprised of an adenosine triphosphatase (ATPase)/helicase domain. These domains are essential for the maturation of the carboxy-terminal portion of the HCV polyprotein and catalyze the cap synthesis of the RNA genome. In this report, human and murine antibody responses induced by NS3 were characterized using a recombinant full-length NS3 (NS3-FL) protein, or the isolated protease or ATPase/ helicase domains, expressed and purified from Escherichia coli. Sera from 40 patients with chronic HCV infection were assayed in enzyme-linked immunoassays (EIAs) for antibody binding to the panel of NS3 proteins. Virtually all patient sera contained antibodies specific for NS3-FL and the ATPase/helicase domain, whereas only 10% of sera reacted with the protease domain of NS3. Human antibodies reactive with NS3-FL were highly restricted to the immunoglobulin G1 (IgG1) isotype and were inhibited by soluble ATPase/helicase, but not by the protease domain. The anti-NS3 (ATPase/helicase) reactivity decreased on denaturation by sodium dodecyl sulfate (SDS) and beta-mercaptoethanol (2ME), suggesting the recognition of nonlinear or conformational B-cell determinants. Similar to infected humans, mice immunized with NS3-FL developed high-titered primary antibody responses to the NS3 ATPase/ helicase domain, whereas an anti-NS3 protease response was not observed after primary or secondary immunizations. Thus, the human and murine humoral immune responses to the HCV NS3 protein are focused on the ATPase/helicase domain, are restricted to the IgG1 isotype in humans, and are conformationally dependent. Unexpectedly, in both species, the NS3 protease domain, present in the context of the full-length NS3, appears to possess low intrinsic immunogenicity in terms of antibody production.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657115     DOI: 10.1002/hep.510280128

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

1.  Isolation and characterization of monoclonal antibodies that inhibit hepatitis C virus NS3 protease.

Authors:  T Ueno; S Misawa; Y Ohba; M Matsumoto; M Mizunuma; N Kasai; K Tsumoto; I Kumagai; H Hayashi
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Characterization of a panel of monoclonal antibodies and mapping the epitopes of hepatitis C virus proteins.

Authors:  O V Masalova; A G Abdulmedzhidova; S N Atanadze; E I Lakina; YuA Semiletov; A N Burkov; T I Ulanova; V V Novikov; V K Pimenov; G Filds; YuE Khudyakov; A A Kushch
Journal:  Dokl Biochem Biophys       Date:  2002 Mar-Apr       Impact factor: 0.788

Review 3.  On the cutting edge: protease-based methods for sensing and controlling cell biology.

Authors:  H Kay Chung; Michael Z Lin
Journal:  Nat Methods       Date:  2020-07-13       Impact factor: 28.547

4.  Characterization of a monoclonal antibody and its single-chain antibody fragment recognizing the nucleoside Triphosphatase/Helicase domain of the hepatitis C virus nonstructural 3 protein.

Authors:  Z X Zhang; U Lazdina; M Chen; D L Peterson; M Sällberg
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

Review 5.  The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target.

Authors:  David N Frick
Journal:  Curr Issues Mol Biol       Date:  2007-01       Impact factor: 2.081

6.  Significance of monoclonal antibodies against the conserved epitopes within non-structural protein 3 helicase of hepatitis C virus.

Authors:  Yixin Bian; Shuoxian Zhao; Shaomei Zhu; Jinfeng Zeng; Tingting Li; Yongshui Fu; Yuanzhan Wang; Xin Zheng; Ling Zhang; Wenjing Wang; Baocheng Yang; Yuanping Zhou; Jean-Pierre Allain; Chengyao Li
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.